Results 61 to 70 of about 12,593 (182)

Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis [PDF]

, 2017
RATIONALE: Respiratory-related hospitalizations of patients with idiopathic pulmonary fibrosis (IPF) are more frequent than those for acute IPF exacerbations and are associated with poor outcomes.
Harold R. Collard, Ley, Brett, Swigris, Jeffrey, Jeffrey Swigris, John L. Stauffer, Stauffer, John L, Willis Chou, Chou, Willis, Brett Ley, Day, Bann-Mo, Karina Raimundo, Raimundo, Karina, Collard, Harold R, Bann-mo Day   +13 more
core   +1 more source

Pregnancy in CTD‐interstitial lung disease: Current evidence, clinical challenges, and a proposed management algorithm

Rheumatology &Autoimmunity, EarlyView.
Summary of pregnancy management in CTD‐ILD across preconception, antenatal, and postpartum phases, emphasizing risk stratification and multidisciplinary care. 6MWT, 6‐min walk test; CTD‐ILD: connective tissue disease‐interstitial lung disease; DLCO, diffusion capacity of the lung for carbon monoxide; FVC, forced vital capacity; MDT, multidisciplinary ...
Khaled Aldhuaina, Ghaydaa Aldabie, Mohammad Abdulsalam, Ali Jawad   +3 more
wiley   +1 more source

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials

, 2011
Background Idiopathic pulmonary fibrosis is a progressive and fatal lung disease with inevitable loss of lung function. The CAPACITY programme (studies 004 and 006) was designed to confirm the results of a phase 2 study that suggested that pirfenidone ...
Paul W Noble, ROTTOLI, PAOLA, . CAPACITY Study Group, Roland M du Bois, Bradford, Williamson Z., Szwarcberg, Javier, Glassberg, Marilyn K., Talmadge E. , King J.r., Costabel, Ulrich, Dominique Valeyre, Javier Szwarcberg, Bradford, Williamson Z, Valeyre, Dominique, Marilyn K Glassberg, for the CAPACITY Study Group, incl., Sahn, Steven A, David Kardatzke, Ulrich Costabel, Carlo Albera, Lancaster, Lisa, Noble, Paul W, Glassberg, Marilyn K, Kardatzke, David, Williamson Z Bradford, Geiser, Thomas, Sahn, Steven A., du Bois, Roland M, Steven A Sahn, Albera, Carlo, Talmadge E King, Lisa Lancaster, Noble, Paul W., King, Talmadge E   +32 more
core   +1 more source

The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial

Respiratory Research, 2011
Background Our phase III clinical trial of pirfenidone for patients with idiopathic pulmonary fibrosis (IPF) revealed the efficacy in reducing the decline of vital capacity (VC) and increasing the progression-free survival (PFS) time by pirfenidone ...
Nakata Koichiro, Takahashi Hiroki, Suga Moritaka, Taguchi Yoshio, Ogura Takashi, Azuma Arata, Ebina Masahito, Kondoh Yasuhiro, Taniguchi Hiroyuki, Sato Atsuhiko, Sugiyama Yukihiko, Kudoh Shoji, Nukiwa Toshihiro   +12 more
doaj   +1 more source

Contemporary Fibrotic Interstitial Lung Disease Outcomes: A Multicentre National Cohort Study

Respirology, EarlyView.
This study determined contemporary transplant‐free survival in fibrotic interstitial lung disease (ILD), identified baseline factors associated with death or transplant, and assessed performance of the ILD‐GAP (Gender, Age, Physiology) index in a contemporary cohort.
Tyler Pitre, Christopher J. Ryerson, Shaun Ong, Kerri A. Johannson, Deborah Assayag, Veronica Marcoux, Martin Kolb, Helene Manganas, Daniel‐Costin Marinescu, Jolene H. Fisher   +9 more
wiley   +1 more source

Potent antioxidant role of Pirfenidone in experimental cirrhosis

, 2008
Three important features must be considered when proposing therapeutic strategies in liver cirrhosis: inflammation, oxidative stress and fibrogenesis. Pirfenidone is a synthetic molecule which oxidative action has not been tested in cirrhosis.
Salazar-Montes, A., Ruiz-Corro, L., Lopez-Reyes, A., Castrejon-Gomez, E., Armendariz-Borunda, J.   +4 more
core   +1 more source

Micellar electrokinetic capillary chromatographic determination of pirfenidone and 5-carboxy-pirfenidone by direct injection of plasma from patients receiving treatment for idiopathic pulmonary fibrosis (IPF)

, 2020
A micellar electrokinetic capillary chromatographic method, a variant of capillary electrophoresis, was developed for the detection and measurement of pirfenidone and 5-carboxy-pirfenidone by direct injection of plasma from patients under treatment for ...
Mangoni, Arduino A, Angelo Zinellu, Fois, Alessandro G, Sotgiu, Elisabetta, Elisabetta Sotgiu, Carru, Ciriaco, Salvatore Sotgia, Ciriaco Carru, Sotgia, Salvatore, Zinellu, Angelo, Paliogiannis, Panagiotis, Arduino A Mangoni, Panagiotis Paliogiannis, Alessandro G Fois   +13 more
core   +1 more source

Honokiol regulates Acute respiratory distress syndrome (ARDS)‐associated pulmonary fibrosis via the miR‐19a‐3p/POSTN axis

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Acute respiratory distress syndrome (ARDS) and subsequent pulmonary fibrosis are associated with high mortality and limited treatment options. Periostin (POSTN) is a profibrotic mediator predicted to be regulated by microRNA‐19a‐3p (miR‐19a‐3p), but the relevance of this axis in ARDS‐associated pulmonary fibrosis remains
Weilun Liu, Hsiaohsuan Wang, Hsuanfu Kuo, Chiahung Yen, Modasang Hua, Chiayuan Chang, Zhiwei Xu, Ifan Liu, Chongchao Hsieh, Chihhsin Hsu, Chiayang Li, Shuchi Wang, Yunghsiang Chen, Menghsuan Cheng, Polen Liu   +14 more
wiley   +1 more source

Effects of Pirfenidone in a Mouse Liver Fibrosis Model [PDF]

, 2017
Liver fibrosis results from chronic damage and excessive regeneration with redundant accumulation of extracellular matrix proteins, including collagen. Liver fibrosis may be caused by infectious, environmental, and autoimmune factors. Liver fibrosis is a
Seniutkin, Oleksii
core   +1 more source

Effectiveness of Pharmacist–Physician Collaborative Management for Patients With Idiopathic Pulmonary Fibrosis Receiving Pirfenidone

Frontiers in Pharmacology, 2020
Background: Pirfenidone is an anti-fibrotic agent used to treat patients with idiopathic pulmonary fibrosis (IPF). Managing adverse drug events and ensuring compliance with pirfenidone treatment for a prolonged period are important to reduce the rate of ...
Yukari Satsuma, Hiroaki Ikesue, Kaori Kusuda, Mami Maeda, Nobuyuki Muroi, Ryobu Mori, Mariko Kogo, Ryosuke Hirabayashi, Kazuma Nagata, Atsushi Nakagawa, Ryo Tachikawa, Keisuke Tomii, Tohru Hashida   +12 more
doaj   +1 more source